We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic Impact of Phosphorylated Mitogen-Activated Protein Kinase Expression in Patients with Metastatic Gastric Cancer.
- Authors
Atmaca, Akin; Pauligk, Claudia; Steinmetz, Kristina; Altmannsberger, Hans-Michael; Jäger, Elke; Al-Batran, Salah-Eddin
- Abstract
Background: This study was designed to investigate the expression of phosphorylated mitogen-activated protein kinase (p-MAPK/Erk1 and Erk2) and its correlation with outcomes in patients with metastatic gastric cancer. Methods: p-MAPK was detected by immunohistochemistry using monoclonal antibodies in a total of 223 formalin-fixed, paraffin-embedded samples obtained from 156 patients who received first-line chemotherapy in a phase III trial. Results: p-MAPK was positive in 93 (59.6%) and negative in 63 (40.4%) of the 156 patients evaluated. Similar rates of p-MAPK positivity were found in primaries (53%) and metastatic lesions (61.4%). Overall survival was significantly shorter in p-MAPK-positive patients (13.7 vs. 8.5 months) in the univariate analysis. However, this prognostic value disappeared as a trend in the multivariate analysis (p = 0.1). There was a strong, positive correlation between p-MAPK and the MIB-1 proliferation index, but MIB-1 did not predict outcomes. Conclusion: p-MAPK expression could be a potential negative prognostic parameter in patients with metastatic gastric cancer treated with chemotherapy. Copyright © 2011 S. Karger AG, Basel
- Subjects
MITOGEN-activated protein kinases; PROTEIN kinases; GASTROINTESTINAL diseases; MONOCLONAL antibodies; DRUG therapy
- Publication
Oncology, 2011, Vol 80, Issue 1/2, p130
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000329063